Linetsky David purchased $682 of PHR (indirect holdings)

Linetsky David (President, Network Solutions) purchased 70 indirectly-held shares of Phreesia, Inc. (PHR) at an average of $9.75 ($9.15–$10.35) across 2 trades on 2026-10-22.

Original reporting
SEC EDGAR · Linetsky David
Published Oct 27, 2026, 1:52 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 2:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHR
Neutral
high confidence
Mentioned
$PHR
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHRNeutralLow
01

Why it matters

The purchase is a routine insider transaction with limited trading relevance.

02

Market read

Minor insider purchase; unlikely to affect stock price materially.

03

What to watch

Potential upcoming corporate actions or guidance that could make insider activity more relevant.

Relevance 3/10Novelty 3/10Timing: post‑market filing on Oct 26

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$PHRNeutralHigh confidence
Context

President of Phreesia purchased 70 shares for $682 via open-market trades, raising his holding to 22,197 shares.

Expected impact

likely slight upward pressure as a buy signal, but negligible due to tiny size.

Evidence & confidence

The transaction amount is trivial relative to market cap; insider buying may be viewed positively but unlikely to move price.

Market effects

No material effect on the health‑tech sector.

None.

None.

Counterpoint

Even small insider buys can precede larger moves; monitor for subsequent purchases.

Key entities

  • Linetsky David

    President, Network Solutions at Phreesia.

  • Phreesia, Inc.

    Provider of patient intake and engagement solutions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHRMed

Phreesia’s (PHR) Profit Turnaround Meets A Cash-Strapped Client Base

Phreesia (PHR) reported Q2 2027 revenue of $129.5M and adjusted EBITDA of $32.9M, marking five straight quarters of positive net income. Revenue grew 10% YoY, with client count and revenue per client also increasing. The company reduced debt by $23M and credited AI for operational efficiencies. However, management warned of increased unpredictability in network solutions revenue due to financial strain on healthcare providers. Phreesia reaffirmed its full-year revenue and EBITDA guidance.

$PHRHighAI 8/10

Phreesia (PHR) Q2 2027 Earnings Call Transcript

Phreesia (PHR) reported Q2 2027 revenue of $129.5M, up 10% YoY, with adjusted EBITDA of $32.9M and net income of $1.9M. AHSCs grew 6% to 4,744. Full-year guidance: revenue $510M-$520M, adjusted EBITDA $125M-$135M. Management noted variability in revenue forecasting and economic pressures on healthcare providers.

$PHRMed

Why Phreesia Stock Got Knocked Down Today

Phreesia (PHR) stock fell 7% Tuesday due to bearish sentiment after Q2 earnings and a downgrade by Raymond James analyst John Ransom. Ransom cited declining organic revenue growth and AI spending pressures. Despite a 10% revenue increase, concerns remain about future performance and market constraints.

$PHRMed

Why Phreesia Stock Tumbled Today

Phreesia (PHR) shares fell 6.33% after reporting Q2 2027 revenue of $129.5M, up 10% YoY, and GAAP net income of $1.9M. While revenue beat estimates, earnings per share missed expectations. The company maintained full-year guidance and highlighted recent product launches.